¼¼°èÀÇ ½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) ½ÃÀå
Real-time PCR (qPCR) and Digital PCR (dPCR)
»óǰÄÚµå : 1659352
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 88 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) ½ÃÀåÀº 2030³â±îÁö 84¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 59¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼¼°èÀÇ ½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) ½ÃÀåÀº 2024-2030³â¿¡ CAGR 6.1%·Î ¼ºÀåÇϸç, 2030³â¿¡´Â 84¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ¸®Æ÷Æ®¿¡¼­ ºÐ¼®ÇÑ ºÎ¹®ÀÇ ÇϳªÀÎ Á¤·® ±â¼úÀº CAGR 5.7%¸¦ ±â·ÏÇϸç, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 76¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. µðÁöÅÐ ±â¼ú ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 9.7%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 16¾ï ´Þ·¯, Áß±¹Àº CAGR 9.8%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) ½ÃÀåÀº 2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 19¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³âÀÇ CAGRÀº 9.8%ÀÔ´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ Áß CAGRÀº °¢°¢ 2.0%¿Í 6.4%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 3.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) : ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

ÃֽŠÁø´Ü¿¡¼­ ½Ç½Ã°£ PCR(qPCR)°ú µðÁöÅÐ PCR(dPCR)ÀÇ Â÷ÀÌÁ¡Àº ¹«¾ùÀΰ¡?

½Ç½Ã°£ PCR(qPCR)°ú µðÁöÅÐ PCR(dPCR)Àº DNA¿Í RNAÀÇ °ËÃâ ¹× Á¤·®È­¿¡ ÀÖÀ¸¸ç, ³ôÀº Á¤È®µµ¿Í ¹Î°¨µµ¸¦ Á¦°øÇÏ´Â ºÐÀÚÁø´ÜÀÇ µÎ °¡Áö ÷´Ü ±â¼úÀÌÁö¸¸, ¹æ¹ý·Ð°ú Àû¿ë¿¡ ÀÖÀ¸¸ç, ±Ùº»ÀûÀ¸·Î ´Ù¸¨´Ï´Ù. ½Ç½Ã°£ PCRÀº Á¤·®Àû PCR(qPCR)À̶ó°íµµ Çϸç, DNA ¿°±â¼­¿­À» ÁõÆøÇϰí Çü±¤Áõ¹éÁ¦ ¶Ç´Â ÇÁ·Îºê¸¦ »ç¿ëÇÏ¿© ÁõÆø »ê¹°ÀÇ ¾çÀ» ½Ç½Ã°£À¸·Î µ¥ÀÌÅÍÈ­ÇÕ´Ï´Ù. ÀÌ Çü±¤À» ÅëÇØ ¿¬±¸ÀÚµéÀº °¢ PCR »çÀÌŬ µ¿¾È ½ÅÈ£ °­µµ¸¦ ÃøÁ¤ÇÏ¿© DNA Ç¥ÀûÀ» Á¤·®È­ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â º´¿øÃ¼ Á¤·®È­ ¹× À¯ÀüÀÚ ¹ßÇö ºÐ¼®°ú °°Àº ¿ëµµ¿¡ ¸Å¿ì À¯¿ëÇÕ´Ï´Ù. ¹Ý¸é, µðÁöÅÐ PCR(dPCR)Àº DNA »ùÇÃÀ» ¼öõ °³ÀÇ ÀÛÀº °³º° ¹ÝÀÀÀ¸·Î ºÐÇÒÇÏ¿© °¢ ºÐÇÒÀÌ DNA Ç¥ÀûÀ» Æ÷ÇÔÇϰųª Æ÷ÇÔÇÏÁö ¾ÊÀ» ¼ö ÀÖµµ·Ï ÇÏ´Â »õ·Î¿î ¹æ¹ýÀÔ´Ï´Ù. ÁõÆø ÈÄ dPCRÀº Çü±¤ÀÌ ¾ç¼ºÀÎ ÆÄƼ¼ÇÀ» °è»êÇÏ¿© qPCR¿¡ ÇÊ¿äÇÑ Ç¥ÁØ °î¼±ÀÌ ÇÊ¿ä ¾ø´Â Á¤È®ÇÑ Àý´ë Á¤·®À» Á¦°øÇÕ´Ï´Ù.

dPCRÀÇ Àý´ë Á¤·® ´É·ÂÀº Á¾¾çÇп¡¼­ Àú¼öÁØ µ¹¿¬º¯ÀÌ °ËÃâÀ̳ª ¸¸¼º °¨¿°¿¡¼­ ¹ÙÀÌ·¯½º ¾ç Æò°¡¿Í °°ÀÌ ³ôÀº Á¤È®µµ¸¦ ÇÊ¿ä·Î ÇÏ´Â ¿ëµµ¿¡ ÀÌ»óÀûÀÔ´Ï´Ù. ¹Ý¸é, qPCRÀº È®À强, È¿À²¼º, È®¸³µÈ ÇÁ·ÎÅäÄÝ·Î ÀÎÇØ ƯÈ÷ »ó´ëÀû Á¤·®À¸·Î ÃæºÐÇÑ ÀÏ»óÀûÀÎ Áø´Ü¿¡ ³Î¸® º¸±ÞµÇ°í ÀÖ½À´Ï´Ù. µÎ ±â¼úÀº °¢°¢ ´Ù¸¥ ¸ñÀûÀ» ´Þ¼ºÇÏÁö¸¸ Áø´Ü¿¡ À־´Â ¼­·Î¸¦ º¸¿ÏÇÏ´Â °æ¿ì°¡ ¸¹À¸¸ç, ¹ÙÀÌ·¯½ºÇÐ, Á¾¾çÇÐ, À¯ÀüÇÐ µî ´Ù¾çÇÑ ¿¬±¸ ºÐ¾ß¿¡¼­ DNA¸¦ ÇöÀúÇÑ Á¤È®µµ·Î °ËÃâ, ÃøÁ¤, ºÐ¼®ÇÒ ¼ö ÀÖ´Â ÅøÀ» Á¦°øÇÕ´Ï´Ù.

qPCR°ú dPCRÀº ¾î¶»°Ô Áúº´ °ËÃâ°ú À¯ÀüüÇÐÀÇ ¹ßÀüÀ» ÃËÁøÇϰí Àִ°¡?

qPCR°ú dPCRÀº °¨¿°º´ Áø´Ü, ¾Ï ¿¬±¸, »êÀü °Ë»ç µî¿¡ Àû¿ëµÇ¾î Áúº´ °ËÃâ ¹× À¯ÀüüÇп¡¼­ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î COVID-19 ÆÒµ¥¹Í »óȲ¿¡¼­ qPCRÀº SARS-CoV-2 °¨¿°À» °ËÃâÇϱâ À§ÇÑ ´ë·® °Ë»ç¿¡ µµ¿òÀÌ µÇ¾î °øÁß º¸°Ç ´ç±¹ÀÌ ¹ÙÀÌ·¯½º È®»êÀ» ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¸¶Âù°¡Áö·Î Á¾¾çÇп¡¼­ qPCRÀº Á¾¾ç ¸¶Ä¿¸¦ ÃøÁ¤Çϰí Ä¡·á È¿°ú¸¦ ¸ð´ÏÅ͸µÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖÀ¸¸ç, ºü¸¥ ó¸® ½Ã°£À¸·Î ÀÎÇØ À¯¿ëÇÏ°Ô »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÇÑÆí, dPCRÀº Èñ±ÍÇÑ À¯ÀüÀÚ »ç°ÇÀ» ¹Î°¨ÇÏ°Ô Á¤·®È­ÇÒ ¼ö ÀÖ´Â ´É·ÂÀº Àúºóµµ µ¹¿¬º¯ÀÌ °ËÃâ¿¡ ¸Å¿ì À¯¿ëÇϸç, ƯÈ÷ ¼Ò·®ÀÇ Ç÷¾× »ùÇÿ¡¼­ ¼øÈ¯ Á¾¾ç DNA¸¦ °ËÃâÇØ¾ß ÇÏ´Â ¾×ü»ý°Ë¿¡¼­ À¯¿ëÇÕ´Ï´Ù.

À¯ÀüüÇÐ ¿¬±¸¿¡¼­ dPCRÀÇ Á¤È®ÇÑ Á¤·®È­´Â À¯ÀüÀÚ ÆíÁý°ú À¯ÀüÀÚ Ä¡·á¿¡ »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ¾ú½À´Ï´Ù. À¯ÀüÀÚ º¹Á¦ÀÇ Á¤È®ÇÑ Á¤·®È­¿Í Èñ±ÍÇÑ À¯ÀüÀÚ º¯ÀÌ °ËÃâÀº ¿¬±¸ÀÇ Áú°ú Ä¡·á È¿°ú¿¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ dPCRÀº ºñħ½ÀÀû »êÀü °Ë»ç¸¦ ¹ßÀü½ÃÄÑ »ê¸ðÀÇ Ç÷¾×¿¡¼­ žÆÀÇ DNA¸¦ Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ°Ô ÇÔÀ¸·Î½á ħ½ÀÀû ½Ã¼úÀÇ Çʿ伺À» ÁÙ¿©ÁÖ°í ÀÖ½À´Ï´Ù. qPCR°ú dPCRÀº ¸ðµÎ À¯Àüü ¿¬±¸¿¡ ±¤¹üÀ§ÇÏ°Ô ±â¿©Çϰí ÀÖÀ¸¸ç, Èñ±Í À¯Àü¼º Áúȯ, ÈļºÀ¯ÀüÇÐ, ÈļºÀ¯ÀüÇÐ, ¾à¸®À¯ÀüÇÐ, À¯Àüü ¿¬±¸, ÈļºÀ¯ÀüÇÐ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸, ¾à¹°À¯ÀüüÇÐÀÇ ¹ß°ßÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù.

qPCR°ú dPCRÀÇ ´É·ÂÀ» È®ÀåÇÏ´Â ±â¼ú ¹ßÀüÀº ¹«¾ùÀΰ¡?

ÀÚµ¿È­, ´ÙÁßÈ­ ¹× µ¥ÀÌÅÍ ºÐ¼®ÀÇ Çõ½ÅÀº qPCR ¹× dPCRÀÌ ´Þ¼ºÇÒ ¼ö ÀÖ´Â ÇѰ踦 ¶Ù¾î³Ñ¾î ´õ ºü¸£°í, ´õ ´Ù¿ëµµÇϸç, ´õ Å« ±Ô¸ðÀÇ ¿ëµµ¿¡ ÀûÇÕÇÏ°Ô µÇ¾ú½À´Ï´Ù. ÀÚµ¿È­¸¦ ÅëÇØ qPCR°ú dPCRÀÇ ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ¿© ÀÓ»ó Áø´Ü ¹× ´ë±Ô¸ð ¿¬±¸¿¡¼­ Áß¿äÇÑ ´ë·®ÀÇ »ùÇÃÀ» ÃÖ¼ÒÇÑÀÇ ¼öÀÛ¾÷À¸·Î ó¸®ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÇÑ ¹øÀÇ ¹ÝÀÀÀ¸·Î ¿©·¯ DNA Ç¥ÀûÀ» °ËÃâÇÏ´Â ¸ÖƼÇ÷º½ÌÀº qPCR°ú dPCR ¸ðµÎ¿¡¼­ °Ë»ç È¿À²À» Å©°Ô Çâ»ó½ÃÄÑ ¿¬±¸ÀÚµéÀÌ ¿©·¯ À¯ÀüÀÚ ¹× º´¿øÃ¼¸¦ µ¿½Ã¿¡ ºÐ¼®ÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ÀÌ·¯ÇÑ ¸ÖƼÇ÷º½Ì ±â´ÉÀº °¨¿° °Ë»ç³ª Á¾¾çÇÐ µî È¿°úÀûÀÎ Ä¡·á °èȹÀ» ¼ö¸³Çϱâ À§ÇØ Á¾ÇÕÀûÀÎ ½ºÅ©¸®´×ÀÌ ÇʼöÀûÀÎ ºÐ¾ß¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù.

¼ÒÇüÈ­ ¹× ÈÞ´ë¿ë PCR Àåºñ´Â qPCR°ú dPCRÀ» ÇöÀå °Ë»ç ¹× ÇöÀå ±â¹Ý Áø´Ü¿¡ Àû¿ëÇÒ ¼ö ÀÖ°Ô ÇÏ¿© Á¢±Ù¼ºÀ» ´õ¿í Çâ»ó½ÃÄ×½À´Ï´Ù. ¿¹¸¦ µé¾î ÇÚµåÇïµå ±â±â¸¦ ÅëÇØ ¿ø°ÝÁö³ª ȯÀÚ Ä§´ë ¿·¿¡¼­ ½Å¼ÓÇÑ ºÐÀÚ °Ë»ç¸¦ ¼öÇàÇÒ ¼ö ÀÖ°Ô µÇ¾î ÀÀ±ÞÀÇ·á ¹× Áö¹æ ÀÇ·á ȯ°æ¿¡¼­ Àû½Ã¿¡ Áø´ÜÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î ¹× µ¥ÀÌÅÍ ºÐ¼®ÀÇ °³¼±Àº PCR µ¥ÀÌÅÍÀÇ ÇØ¼®À» º¯È­½Ã۰í ÀÖÀ¸¸ç, ÀΰøÁö´É ¹× ¸Ó½Å·¯´× ¾Ë°í¸®ÁòÀº °á°ú¸¦ ÃÖÀûÈ­Çϰí, ÆÐÅÏÀ» ½Äº°Çϰí, À¯Àü Áúȯ ¹× °¨¿°¼º Áúȯ¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®À» Á¦°øÇÏ´Â µ¥ µµ¿òÀ» ÁÖ°í ÀÖ½À´Ï´Ù. ´õ ºü¸¥ ÀÀ´ä ½Ã°£, ´õ ³ôÀº ¹Î°¨µµ¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© qPCR°ú dPCRÀ» ºÐÀÚÁø´Ü ¹× À¯Àüü ¿¬±¸ÀÇ ÁøÈ­ÇÏ´Â ¿ä±¸¿¡ ÀûÀÀÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

½Ç½Ã°£ PCR(qPCR) ¹× µðÁöÅÐ PCR(dPCR) ½ÃÀåÀÇ ¼ºÀå ¿øµ¿·ÂÀº?

qPCR ¹× dPCR ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀº Á¤¹ÐÁø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ±â¼ú ¹ßÀü, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡ µîÀ̸ç, COVID-19 °Ë»ç¿¡¼­ qPCR ¹× dPCRÀÌ Â÷ÁöÇÏ´Â Áß¿äÇÑ ¿ªÇÒ¿¡¼­ ¾Ë ¼ö ÀÖµíÀÌ °¨¿°º´ ÅðÄ¡¿¡ ÀÖÀ¸¸ç, qPCR ¹× dPCRÀÇ Á߿伺Àº ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü¿¡ ´ëÇÑ ºü¸¥ Áø´Ü¿¡ ´ëÇÑ ¼¼°è ´ÏÁ ºÎ°¢½ÃŰ¸ç ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù. Á¾¾çÇп¡¼­´Â °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ µû¶ó Ä¡·á¹ýÀ» Á¶Á¤ÇÏ´Â Á¤¹ÐÀÇ·áÀÇ ºÎ»óÀ¸·Î µ¹¿¬º¯À̸¦ °¨ÁöÇϰí Ä¡·á ¹ÝÀÀÀ» ¸ð´ÏÅ͸µÇϱâ À§ÇØ qPCR ¹× dPCR°ú °°Àº °íÁ¤¹Ð Á¤·®È­ Åø¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ dPCRÀÇ Àý´ëÀûÀÎ Á¤·®È­ ´É·ÂÀº Èñ±Í µ¹¿¬º¯ÀÌ ¹× ³·Àº ¼öÁØÀÇ º´¿øÃ¼ °ËÃâ¿¡ ÇʼöÀûÀ̸ç, ¾×ü»ý°Ë ¹× Á¶±â ¾Ï °ËÃâ°ú °°Àº ¿ëµµ¿¡¼­ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

ÀÌ¿Í ÇÔ²² ÀÚµ¿È­, ¼ÒÇüÈ­, ´ÙÁßÈ­¸¦ Æ÷ÇÔÇÑ PCR ±â¼úÀÇ Çõ½ÅÀº qPCR°ú dPCRÀ» ´õ¿í Ä£¼÷Çϰí È¿À²ÀûÀ¸·Î ¸¸µé¾î ÀÓ»ó Áø´Ü, ȯ°æ ¸ð´ÏÅ͸µ, ³ó¾÷ »ý¸í°øÇп¡ ´ëÇÑ ÀÀ¿ëÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ¿¬±¸, ƯÈ÷ À¯ÀüÀÚ Ä¡·á ¹× À¯ÀüÀÚ ÆíÁýÀÇ ±Þ¼ÓÇÑ ¼ºÀåÀ¸·Î ÀÎÇØ ¿¬±¸ÀÚµéÀÌ À¯ÀüÀÚ º¯ÇüÀÇ °á°ú¸¦ Æò°¡Çϱâ À§ÇØ Á¤È®ÇÑ ÃøÁ¤ÀÌ ÇÊ¿äÇϹǷΠdPCR¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ¿Í ¼ÒºñÀÚ ¸ðµÎ ºñħ½ÀÀû Áø´Ü ¹æ¹ýÀ» ¼±È£ÇÔ¿¡ µû¶ó qPCR°ú dPCRÀº »êÀü °Ë»ç ¹× Á¶±â ¾Ï Áø´Ü°ú °°Àº ºñħ½ÀÀû °Ë»ç¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇÔÀ¸·Î½á ±× ÀαⰡ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ãß¼¼¸¦ Á¾ÇÕÇϸé Á¤¹ÐÁø´Ü, ¸ÂÃã Ä¡·á, ÃֽŠÀ¯Àüü ºÐ¼®¿¡¼­ qPCR°ú dPCRÀÇ ¿ªÇÒÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ±â¼úÀº ÇコÄɾî¿Í ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ¹Ì·¡ Ãʼ®À¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±â¼ú(Á¤·®, µðÁöÅÐ), Á¦Ç° À¯Çü(¼Ò¸ðǰ/½Ã¾à, Àåºñ, ¼ÒÇÁÆ®¿þ¾î/¼­ºñ½º), ¿ëµµ(Á¶»ç, ÀÓ»ó, ±âŸ ¿ëµµ)

Á¶»ç ´ë»ó ±â¾÷ÀÇ ¿¹(ÃÑ 32»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå °³¿ä

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Real-time PCR (qPCR) and Digital PCR (dPCR) Market to Reach US$8.4 Billion by 2030

The global market for Real-time PCR (qPCR) and Digital PCR (dPCR) estimated at US$5.9 Billion in the year 2024, is expected to reach US$8.4 Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Quantitative Technology, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$7.6 Billion by the end of the analysis period. Growth in the Digital Technology segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.6 Billion While China is Forecast to Grow at 9.8% CAGR

The Real-time PCR (qPCR) and Digital PCR (dPCR) market in the U.S. is estimated at US$1.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2030 trailing a CAGR of 9.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.2% CAGR.

Real-Time PCR (qPCR) and Digital PCR (dPCR): Key Trends & Drivers Summarized

What Distinguishes Real-Time PCR (qPCR) from Digital PCR (dPCR) in Modern Diagnostics?

Real-time PCR (qPCR) and digital PCR (dPCR) are two advanced techniques in molecular diagnostics that offer high accuracy and sensitivity in detecting and quantifying DNA and RNA, yet they differ fundamentally in methodology and applications. Real-time PCR, also known as quantitative PCR (qPCR), amplifies DNA sequences and provides real-time data on the quantity of amplified product using fluorescent dyes or probes. This fluorescence allows researchers to quantify the DNA target by measuring signal intensity during each PCR cycle, making it highly useful in applications like pathogen quantification and gene expression analysis. In contrast, digital PCR (dPCR) is a newer method that partitions a DNA sample into thousands of tiny individual reactions, allowing each partition to either contain or not contain the DNA target. Following amplification, dPCR counts the partitions with positive fluorescence, offering precise, absolute quantification without the need for a standard curve, as required in qPCR.

The absolute quantification capability of dPCR makes it ideal for applications needing high precision, such as detecting low-level mutations in oncology or assessing viral loads in chronic infections. Meanwhile, qPCR remains widely popular due to its scalability, efficiency, and established protocols, particularly in routine diagnostics, where relative quantification is sufficient. Both technologies serve distinct purposes but often complement each other in diagnostics, offering tools to detect, measure, and analyze DNA with remarkable accuracy across diverse research areas, including virology, oncology, and genetics.

How Are qPCR and dPCR Driving Advances in Disease Detection and Genomics?

qPCR and dPCR are pivotal in disease detection and genomics, with applications spanning infectious disease diagnostics, cancer research, prenatal screening, and more. qPCR is especially valuable in infectious disease testing, where its rapid, quantitative capabilities enable timely diagnosis and management of pathogen loads. For example, during the COVID-19 pandemic, qPCR was instrumental in mass testing to detect SARS-CoV-2 infections, allowing public health authorities to monitor virus spread. Similarly, in oncology, qPCR assists in measuring tumor markers and monitoring treatment efficacy, where its fast turnaround time is beneficial. Meanwhile, dPCR’s ability to quantify rare genetic events with high sensitivity has made it invaluable in detecting low-frequency mutations, particularly useful in liquid biopsies, where circulating tumor DNA must be detected from a small blood sample.

In genomics research, dPCR’s precise quantification has opened new possibilities for gene editing and gene therapy, where accurately quantifying gene copies or detecting rare genetic variants is critical for research quality and therapeutic efficacy. Additionally, dPCR is advancing non-invasive prenatal testing, allowing for accurate detection of fetal DNA from maternal blood, reducing the need for invasive procedures. This ultra-sensitive technology is also invaluable in monitoring minimal residual disease in cancer, where even a trace amount of tumor DNA can be detected post-treatment, providing early warning signs of recurrence. Both qPCR and dPCR contribute extensively to genomic studies, enabling discoveries in rare genetic disorders, epigenetic research, and pharmacogenomics, thus driving precision medicine forward with accurate and actionable data.

What Technological Advancements Are Expanding qPCR and dPCR Capabilities?

Innovations in automation, multiplexing, and data analysis are pushing the boundaries of what qPCR and dPCR can achieve, making them faster, more versatile, and suitable for larger-scale applications. Automation has streamlined qPCR and dPCR workflows, allowing laboratories to handle higher sample volumes with minimal manual input, critical in clinical diagnostics and large-scale studies. Multiplexing, where multiple DNA targets are detected within a single reaction, has significantly improved testing efficiency in both qPCR and dPCR, enabling researchers to analyze multiple genes or pathogens simultaneously. This multiplexing capability is particularly valuable in fields like infectious disease testing and oncology, where comprehensive screening is essential for effective treatment planning.

Miniaturization and portable PCR devices have further enhanced accessibility, allowing qPCR and dPCR to be applied in point-of-care testing and field-based diagnostics. For example, handheld devices now make it possible to conduct rapid molecular testing in remote areas or at a patient’s bedside, which is essential for timely diagnostics in emergency and rural healthcare settings. Improvements in software and data analytics have also transformed PCR data interpretation, with artificial intelligence and machine learning algorithms helping to optimize results, identify patterns, and provide deeper insights into genetic and infectious diseases. These advancements in PCR technology enable broader diagnostic applications, faster response times, and greater sensitivity, making qPCR and dPCR adaptable to the evolving needs of molecular diagnostics and genomic research.

What Is Driving Growth in the Real-Time PCR (qPCR) and Digital PCR (dPCR) Market?

The growth in the qPCR and dPCR market is driven by increasing demand for precision diagnostics, technological advancements, and a rising focus on personalized medicine. qPCR and dPCR’s importance in the fight against infectious diseases, as evidenced by their pivotal role in COVID-19 testing, has highlighted the need for fast, accurate diagnostics worldwide, fueling market expansion. In oncology, the rise of precision medicine—where treatments are tailored based on individual genetic profiles—has spurred demand for highly accurate, quantifiable tools like qPCR and dPCR to detect mutations and monitor treatment responses. Additionally, dPCR’s absolute quantification capability makes it indispensable in detecting rare mutations or low-level pathogens, a necessity in applications like liquid biopsy and early-stage cancer detection.

In parallel, innovations in PCR technology, including automation, miniaturization, and multiplexing, are making qPCR and dPCR more accessible and efficient, broadening their applications in clinical diagnostics, environmental monitoring, and agricultural biotechnology. The rapid growth in genetic research, particularly in gene therapy and genome editing, has also increased demand for dPCR as researchers need precise measurements to assess gene modification outcomes. Furthermore, as healthcare providers and consumers alike push for more non-invasive diagnostic methods, qPCR and dPCR continue to grow in popularity, offering reliable solutions for non-invasive tests like prenatal screening and early cancer detection. Collectively, these trends underline the expanding role of qPCR and dPCR in precision diagnostics, personalized treatment, and modern genomics, positioning these technologies as cornerstones in the future of healthcare and biotechnology.

SCOPE OF STUDY:

The report analyzes the Real-time PCR (qPCR) and Digital PCR (dPCR) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Quantitative, Digital); Product Type (Consumables & Reagents, Instruments, Software & Services); Application (Research, Clinical, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â